Pharmacy Grand Rounds
It’s Not Just the Lungs? Non-Pulmonary Complications of Cystic Fibrosis

• ACPE Universal Activity Number (UAN): JA0000238-0000-21-004-L01-P
• Session Type: Knowledge-based
• CE Credits: A maximum of 0.75 contact hour (0.075 CEU) for the following: 
  • AAPA Category 1 CME Credits
  • ACPE
  • AMA PRA Category 1 Credits™
  • ANCC

• Session Fee: Free for Mayo Clinic staff

SESSION LOCATIONS

Live Session: (11:00am - 11:45am CST) 

Until further notice, learners must watch Pharmacy Grand Rounds live via the web by going to the Video Exchange and selecting “Pharmacy Grand Rounds” in the “Streaming Now” section.

Participants may attend by viewing: Live Webcast
Video Recording - access two weeks after session date

COURSE DESCRIPTION
Cystic fibrosis affects nearly 70,000 people worldwide, with greater than 30,000 of those individuals living in the United States alone. While typically cystic fibrosis is thought of as a pulmonary-only disorder, the absence of CFTR impacts other organs, including the lungs, pancreas, liver, and gastrointestinal tract. This presentation will review the non-pulmonary complications associated with cystic fibrosis, as well as describe appropriate treatment recommendations.

LEARNING OBJECTIVES
At the conclusion of this knowledge-based CE session, participants should be able to:

• Describe the pathophysiology of non-pulmonary clinical manifestations in cystic fibrosis (CF)
• Review guideline recommendations and primary literature to manage non-pulmonary CF complications
• Select appropriate treatment options for patients with non-pulmonary CF complications

Session Announcement.pdf

01.05.2021 - Presentation Slides.pdf

FACULTY INFORMATION

Ashley O. Otto, PharmD, BCPS
Internal Medicine Clinical Pharmacist
Mayo Clinic Hospital - Rochester, MN

Ashley received a Doctor of Pharmacy degree from Purdue University in West Lafayette, IN with subsequent completion of PGY1 and PGY2 Internal Medicine training at Virginia Commonwealth University Health System in Richmond, VA. She is currently an internal medicine pharmacist at Mayo Clinic Hospital – Rochester with practice interests in infectious disease, HIV, and nephrology.

DISCLOSURE STATEMENTS
As a provider accredited by Joint Accreditation Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science (Mayo Clinic School of CPD) must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of these relevant financial relationships will be published in activity materials so those participants in the activity may formulate their own judgments regarding the presentation.

Listed below are individuals with control of the content of this program:

The faculty report the following relationships:

• Ashley O. Otto, PharmD
  • Declares no financial relationship(s) pertinent to this session
  • Declares off-label use of devices and medications will be discussed during this presentation, including:
    • Diatrizoate meglumine
    • Diatrizoate sodium
    • Polyethylene glycol 3350 and electrolytes oral solution
    • Ursodeoxycholic acid (ursodiol)

Course Director and Planning Committee Members declare no relevant financial relationship(s) pertinent to this session. 

Members include:

• Jennifer Elmer, DNP, APRM, CCNS, FCCM
• Michael Huckabee, MPAS, PA-C, PhD
• Sarah Jane Kotval
• Wayne (Nick) Nicholson, MD, PharmD, BCPS
• Garrett Schramm, PharmD, BCPS
• Lee Skrupky, PharmD, BCPS
• Brenda Stellmaker